Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

OBJECTIVE--To investigate the effects of a novel specific renin inhibitor, RO 42-5892, with high affinity for human renin (Ki = 0.5 x 10(-9) mol/l), on plasma renin activity and angiotensin II concentration and on 24 hour ambulatory blood pressure in essential hypertension. DESIGN--Exploratory study in which active treatment was preceded by placebo. SETTING--Inpatient unit of teaching hospital. PATIENTS--Nine men with uncomplicated essential hypertension who had a normal sodium intake. INTERVENTIONS--Two single intravenous doses of RO 42-5892 (100 and 1,000 micrograms/kg in 10 minutes) given to six patients and one single oral dose (600 mg) given to the three others as well as to three of the patients who also received the two intravenous doses. RESULTS--With both intravenous and oral doses renin activity fell in 10 minutes to undetectably low values, while angiotensin II concentration fell overall by 80-90% with intravenous dosing and by 30-40% after the oral dose. Angiotensin II concentration was back to baseline four hours after the low and six hours after the high intravenous dose and remained low for at least eight hours after the oral dose. Blood pressure fell rapidly both after low and high intravenous doses and after the oral dose and remained low for hours. With the high intravenous dose the daytime (0900-2230), night time (2300-0600), and next morning (0630-0830) systolic blood pressures were significantly (p less than 0.05) lowered by 12.5 (95% confidence interval 5.6 to 19.7), 12.2 (5.4 to 19.3), and 10.7 (3.2 to 18.5) mm Hg respectively, and daytime diastolic pressure was lowered by 9.3 (2.2 to 16.8) mmHg. With the oral dose daytime, night time, and next morning systolic blood pressures were lowered by 10.3 (5.5 to 15.4), 10.5 (4.2 to 17.2), and 9.7 (4.0 to 15.6) mm Hg, and daytime and night time diastolic pressures were lowered by 5.8 (0.9 to 11.0) and 6.0 (0.3-12) mm Hg respectively. CONCLUSIONS--The effect of the inhibitor on blood pressure was maintained over a longer period than its effect on angiotensin II. RO 42-5892 is orally active and has a prolonged antihypertensive effect in patients who did not have sodium depletion. This prolonged effect seems to be independent, at least in part, of the suppression of circulating angiotensin II.

[1]  H. Pieterman,et al.  Metabolism and Production of Angiotensin I in Different Vascular Beds in Subjects With Hypertension , 1990, Hypertension.

[2]  C. Aalkjaer,et al.  The contractile effects of porcine tetradecapeptide renin substrate in human resistance vessels: evidence of activation by vascular wall renin and serine proteases. , 1989, Journal of hypertension.

[3]  J. Ménard,et al.  Hemodynamic and Biochemical Consequences of Renin Inhibition by Infusion of CGP 38560A in Normal Volunteers , 1989, Hypertension.

[4]  A. Delabays,et al.  Hemodynamic and Humoral Effects of the New Renin Inhibitor Enalkiren in Normal Humans , 1989, Hypertension.

[5]  T. Ogihara,et al.  Renin Inhibitor and Converting Enzyme Inhibitors Suppress Vascular Angiotensin II , 1989, Hypertension.

[6]  J. Ménard,et al.  Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. , 1989, British journal of clinical pharmacology.

[7]  H. Kleinert,et al.  Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys. , 1989, Hypertension.

[8]  A. J. Man in 't Veld,et al.  Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. , 1988, Circulation.

[9]  S. Rosenberg,et al.  Cardiovascular actions of the primate-selective renin inhibitor, A-62198. , 1988, The Journal of pharmacology and experimental therapeutics.

[10]  V. Dzau,et al.  Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. , 1987, Circulation research.

[11]  D. Campbell.  Tissue Renin‐Angiotensin System: Sites of Angiotensin Formation , 1987, Journal of cardiovascular pharmacology.

[12]  W. Kati,et al.  An orally active inhibitor of renin. , 1986, Hypertension.

[13]  V. Dzau.  Significance of the vascular renin-angiotensin pathway. , 1986, Hypertension.

[14]  S. Ball,et al.  A study of the renin inhibitor H142 in man. , 1985, Journal of hypertension.

[15]  J. Wood,et al.  Effects of a specific and long-acting renin inhibitor in the marmoset. , 1985, Hypertension.

[16]  B. Waeber,et al.  True Versus Immunoreactive Angiotensin II in Human Plasma , 1985, Hypertension.

[17]  J. A. Oliver,et al.  Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. , 1984, The Journal of clinical investigation.

[18]  M. Miyazaki,et al.  Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. , 1984, Journal of hypertension.

[19]  A. J. Man in 't Veld,et al.  Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. , 1983, Hypertension.

[20]  E. Haber,et al.  Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action. , 1983, Transactions of the Association of American Physicians.

[21]  E. Raftery,et al.  Ambulant blood pressure: reproducibility and the assessment of interventions. , 1980, Clinical science.